Today (July 11), CDE official website showed that Zhejiang Heze Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Heze Pharmaceutical")'s HZ012 injection obtained the implied permission of clinical trial for adult patients with BMI of 28kg/m2 and above (obesity) or BMI of 24kg/m2 and above (overweight) and accompanied by at least one obesity complication to assist in low calorie diet and increase exercise for weight management.
HZ012 is a GLP-1R/GIPR dual agonist developed under the leadership of Heze Pharmaceutical.
In addition to HZ012, Heze Pharmaceutical also has two GLP-1R/GIPR agonists, namely HZ010 and P29. Among them, HZ010 was jointly developed by Doyle Biotech and Heze Pharmaceuticals, and Phase I clinical trials were conducted in October 2022. P29 was also approved for clinical use in April this year. Both drugs are intended to treat type 2 diabetes.
HZ012 has been approved for clinical use this time, with an indication for obesity. HZ012 is also the first GLP-1R/GIPR agonist approved by Heze Pharmaceutical to conduct obesity clinical trials.
In addition to HZ012, Heze Pharmaceutical also has two GLP-1R/GIPR agonists, namely HZ010 and P29. Among them, HZ010 was jointly developed by Doyle Biotech and Heze Pharmaceuticals, and Phase I clinical trials were conducted in October 2022. P29 was also approved for clinical use in April this year. Both drugs are intended to treat type 2 diabetes.
HZ012 has been approved for clinical use this time, with an indication for obesity. HZ012 is also the first GLP-1R/GIPR agonist approved by Heze Pharmaceutical to conduct obesity clinical trials.
40 year old target：Rolling into a new track of weight loss
GLP-1 receptor has been one of the important targets for the treatment of type 2 diabetes for more than 40 years. GLP-1 is a type of pancreatic stimulating hormone that can be applied independently in clinical practice, with high organ selectivity and few side effects.
With the popularity of Smeglutide's "magic effect" on weight loss, this "old target" of diabetes has been labeled as "weight loss". In 2022, Novo Nordisk, relying on Smeaglutide, will win 10 billion US dollars, adding to the research and development of GLP-1 drugs.
In terms of weight loss, in addition to smectide, another drug also performs well.
In 2022, the GLP-1/GIP dual agonist tilporide was approved for marketing in the United States for the treatment of type 2 diabetes. Tilposide achieved sales of $568.5 million in less than a year; In the first quarter of 2023, it reached 536.4 million US dollars, with an astonishing growth rate.
With the popularity of Smeglutide's "magic effect" on weight loss, this "old target" of diabetes has been labeled as "weight loss". In 2022, Novo Nordisk, relying on Smeaglutide, will win 10 billion US dollars, adding to the research and development of GLP-1 drugs.
In terms of weight loss, in addition to smectide, another drug also performs well.
In 2022, the GLP-1/GIP dual agonist tilporide was approved for marketing in the United States for the treatment of type 2 diabetes. Tilposide achieved sales of $568.5 million in less than a year; In the first quarter of 2023, it reached 536.4 million US dollars, with an astonishing growth rate.
In April 2022, Lilly released key data from a global phase 3 clinical trial of tilposide in the treatment of obesity or overweight populations. The results showed that the three doses of tilposide (5mg, 10mg, 15mg) in the treatment group had significantly better weight loss effects than the placebo control group at 72 weeks. At the same time, the subgroup receiving the highest dose (15mg) of treatment had an average weight loss of 22.5% (approximately 24 kilograms), with 63% of the subjects having a weight loss of at least 20%. Tilposide is the first drug in phase 3 clinical trials to reduce body weight by an average of over 20%.
In other words, the weight loss effect of Tilposide is better than that of Smegglutide.
In China, telposide is still in the clinical stage. In February of this year, Lilly announced positive results in a phase III clinical trial of telposide for obese or overweight adult patients in China. In the experiment, the overall safety of Tilposide was similar to previous experimental reports.
In addition to the aforementioned drugs, Rita Lilly's GLP-1R/GIPR/GCGR triple inhibitor Retarutide is also worth looking forward to.
Recently, the top medical journal, the New England Journal of Medicine, published the results of the second clinical trial of Retatrutide, which showed that this drug could reduce the weight of the subjects by 24.2% in 48 weeks, surpassing all existing weight loss drugs.
In other words, the weight loss effect of Tilposide is better than that of Smegglutide.
In China, telposide is still in the clinical stage. In February of this year, Lilly announced positive results in a phase III clinical trial of telposide for obese or overweight adult patients in China. In the experiment, the overall safety of Tilposide was similar to previous experimental reports.
In addition to the aforementioned drugs, Rita Lilly's GLP-1R/GIPR/GCGR triple inhibitor Retarutide is also worth looking forward to.
Recently, the top medical journal, the New England Journal of Medicine, published the results of the second clinical trial of Retatrutide, which showed that this drug could reduce the weight of the subjects by 24.2% in 48 weeks, surpassing all existing weight loss drugs.
Brief Summary
Not long ago, Liraglutide injection of Huadong Medicine was approved as an indication for weight loss; Only in China, more than ten GLP-1 inhibitors have been proposed for weight loss, such as HS-20094 of Hansen Pharmaceutical, HRS9531 of Jiangsu Hengrui Medicine, GMA-106 of Hongyun Huaning and GZR-18 of Ganli Pharmaceutical. The competition in the domestic weight-loss market is becoming increasingly fierce, and HZ012 has just started. How the final performance will be, we can wait and see.
